MedTrace Logo

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NCT07187752 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1039

Last updated 2025-09-23

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of neoadjuvant trastuzumab, pertuzumab and chemotherapy chosen by the investigators and identify the molecular characterization and subtypes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Conditions

Interventions

DRUG

Trastuzumab

Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks)

DRUG

Pertuzumab

Pertuzumab (loading dose 840 mg, followed by 420 mg every 3 weeks)

DRUG

Chemotherapy

Chemotherapy chosen by the investigators.

PROCEDURE

Excision of tumor/mastectomy

Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-12-31
Completion
2027-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07187752 on ClinicalTrials.gov